Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at
The aim of this study is to evaluate usual care versus biomarker-directed care (using blood eosinophil counts) for the management of asthma patients in primary care setting. The study hypothesizes that BEC is a valuable biomarker that can guide asthma treatment, and result in reduction in asthma exacerbations, better s
| Condition(s) | Asthma Exacerbations, Biomarkers / Blood, Eosinophil Blood Count |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The aim of this study is to evaluate usual care versus biomarker-directed care (using blood eosinophil counts) for the management of asthma patients in primary care setting. The study hypothesizes that BEC is a valuable biomarker that can guide asthma treatment, and result in reduction in asthma exacerbations, better symptom control and improvement in quality of life compared to usual arm in mild to moderate asthma patients in the primary care setting. Researchers would compare using blood eosinophil count guided to usual care to see if biomarker-directed asthma treatment and management |
| Who can participate | Inclusion Criteria: 1. Singaporeans or Singapore Permanent Residents 2. Patients aged ≥21 to 65 years old 3. Physician diagnosed asthma for duration of at least 4 weeks 4. On or will be initiated on Global Initiative for Asthma (GINA) 2025 step 1-3) treatment 5. No asthma exacerbations\* in the preceding 4 weeks before randomisation 6. Able and willing to attend study appointments approximately every 4-monthly over a 1-year period 7. Able to provide informed consent 8. Stable cardiovascular status (i.e. controlled hypertension, no active symptoms of heart disease or arrhythmias) \*Exacerbations are defined as worsening of asthma symptoms requiring systemic corticosteroid for 3 or more days, emergency department visit, or hospitalization Exclusion Criteria: 1. History of life-threatening as |
| Ages | 21 Years to 65 Years |
| Sex | All |
| Lead sponsor | National Healthcare Group Polyclinics |
| Locations | Singapore, Singapore |
| Start date | 2025-12-03 |
| NCT ID | NCT07486401 |
| Official listing | https://clinicaltrials.gov/study/NCT07486401 |